<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="606">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 07, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00843518</url>
  </required_header>
  <id_info>
    <org_study_id>12541</org_study_id>
    <secondary_id>H6N-MC-LEAQ</secondary_id>
    <nct_id>NCT00843518</nct_id>
  </id_info>
  <brief_title>Treatment for Aggression and Agitation in Patients With Alzheimer's Disease</brief_title>
  <official_title>Assessment of LY451395 for Neuropsychiatric Symptoms of Aggression and Agitation in Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether this drug can help symptoms of aggression
      and agitation in patients with Alzheimer's disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary purpose of this study is to help answer the following research questions:

        -  Whether this drug can help symptoms of aggression and agitation in subjects with
           Alzheimer's Disease.

        -  The safety of this drug and any side effects that might be associated with it.

        -  How this drug compares to placebo.

      During the 12-week period of this study, the patient will have an equal chance of receiving 1
      of the 2 treatment groups the active drug or the placebo.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change in the 4-item agitation/aggression subscale of the Neuropsychiatric Inventory (NPI-12). Change in measurement of verbal and physical agitation and aggression symptoms.</measure>
    <time_frame>At baseline, 3 weeks, 6 weeks, 9 weeks, 12 weeks, and 13 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy by means of the Cohen-Mansfield Agitation Inventory (CMAI-C)</measure>
    <time_frame>At baseline, 3 weeks, 6 weeks, 9 weeks, and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy by means of the Neuropsychiatric Inventory -10 item Version (NPI-10)</measure>
    <time_frame>At baseline, 3 weeks, 6 weeks, 9 weeks, 12 weeks, and 13 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy by means of the Cornell Scale for Depression in Dementia (CSDD)</measure>
    <time_frame>At baseline, 6 weeks, and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy by means of the Frontal System Behaviors Scale (FrsBe)</measure>
    <time_frame>At baseline, 6 weeks, and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy by means of the Clinical Global Impression-Severity-Agitation/Aggressive (CGI-S-A/A)</measure>
    <time_frame>At baseline, week 1, week 2, week 3, week 4, week 5, week 6, week 7, week 8, week 9, week 10, week, 11, week 12, and week 13</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>By means of the Clinical Global Impression,Severity-Global Functioning (CGI-S-GF)</measure>
    <time_frame>At baseline, 6 weeks, and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy by means of the Alzheimer's Disease Assessment Scale, Cognitive, Subscale 14-item(ADAS-Cog)</measure>
    <time_frame>At baseline, 6 weeks, and 12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">98</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>LY451395</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY451395</intervention_name>
    <description>3 mg BID oral 12 weeks. May be reduced to 1 mg if unable to tolerate</description>
    <arm_group_label>LY451395</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>BID oral 12 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Community-dwelling patients with a diagnosis of probable Alzheimer's disease (AD),
             based on the disease diagnostic criteria, and with Mini Mental State Examination
             (MMSE) score from 6 to 26 inclusive, NPI-10 total score greater than or equal to 10,
             and significant neuropsychiatric symptoms.

          -  Are men or women at least 60 years old.

          -  Weigh greater than or equal to 45 kg.

          -  Have clinically significant and persistent verbal or physical agitation and/or verbal
             or physical aggression behaviors that are disruptive to daily functioning or
             potentially harmful.

          -  Understand English.

          -  Have a reliable and actively involved caregiver who must be able to communicate in
             English and be willing to comply with protocol requirements.

        Exclusion Criteria:

          -  Have delirium.

          -  Meet criteria for vascular dementia.

          -  Have an MRI or CT scan on file since the onset of symptoms of AD and performed within
             the past 24 months that is inconsistent with a diagnosis of AD.

          -  Have a current, required use or expected use of psychoactive drugs or other
             medications not allowed in this trial.

          -  Have currently active significant medical problems that are not allowed in this trial
             or other brain disorders.

          -  Have received acetylcholinesterase inhibitor (AChEIs) or memantine for less than 4
             months, or have less than 2 months of stable therapy on these treatments by Visit 2.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877.CTLilly (1-877-285-4559) or 1-317-615-4559 Mon-Fri 9 AM-5PM Easter time (UTC/GMT-5 hours, EST</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Costa Mesa</city>
        <state>California</state>
        <zip>92626</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hamden</city>
        <state>Connecticut</state>
        <zip>06518</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Easton</city>
        <state>Maryland</state>
        <zip>21601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Flowood</city>
        <state>Mississippi</state>
        <zip>39232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Toms River</city>
        <state>New Jersey</state>
        <zip>08755</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Staten Island</city>
        <state>New York</state>
        <zip>10312</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hickory</city>
        <state>North Carolina</state>
        <zip>28601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Norristown</city>
        <state>Pennsylvania</state>
        <zip>19401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78757</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bennington</city>
        <state>Vermont</state>
        <zip>05201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Waukesha</city>
        <state>Wisconsin</state>
        <zip>53188</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <!-- Old date names will be dropped in a few months (sometime in 2018)                        -->
  <lastchanged_date>September 20, 2011</lastchanged_date>
  <firstreceived_date>February 12, 2009</firstreceived_date>
  <firstreceived_results_disposition_date>September 20, 2011</firstreceived_results_disposition_date>
  <!-- New date names                                                                           -->
  <study_first_submitted>February 12, 2009</study_first_submitted>
  <study_first_submitted_qc>February 12, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 13, 2009</study_first_posted>
  <disposition_first_submitted>September 20, 2011</disposition_first_submitted>
  <disposition_first_submitted_qc>September 20, 2011</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">September 26, 2011</disposition_first_posted>
  <last_update_submitted>September 20, 2011</last_update_submitted>
  <last_update_submitted_qc>September 20, 2011</last_update_submitted_qc>
  <last_update_posted type="Actual">October 24, 2017</last_update_posted>
  <!-- End of dates                                                                             -->
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Agitation and Aggression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Psychomotor Agitation</mesh_term>
    <mesh_term>Aggression</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

